×
ADVERTISEMENT

Braftovi

Erbitux Approved for Use With Braftovi for BRAF V600E–Mutated mCRC

The FDA granted approval of a new indication for cetuximab (Erbitux, Lilly) in combination with encorafenib ...

OCTOBER 4, 2021

Braftovi Approved to Treat BRAF-Mutated CRC in Combination With Erbitux

The FDA approved the use of encorafenib (Braftovi, Pfizer) in combination with cetuximab (Erbitux, ImClone) in ...

APRIL 21, 2020

FDA Approves Encorafenib and Binimetinib Combo for Melanoma With BRAF Mutations

The FDA approved the use of Braftovi and Mektovi in combination for patients with unresectable or metastatic ...

JUNE 29, 2018

Load more